After receiving approval for two HIV drugs, Delstrigo (doravirine/lamivudine/tenofovir disproxil fumarate) and Pifeltro (doravirine), Merck should be expecting strong sales but probably unlikely to be at blockbuster levels, according to senior pharma analyst at GlobalData.
HIV
The double-approval from the US Food and Drug Administration (FDA) has come at a fortuitous time for the company as revealed by Thomas Moore from GlobalData: “This approval comes at a good time for Merck & Co, which will be looking to mitigate an anticipated drop in sales for its HIV portfolio due to an erosion of market share for the Isentress franchise due to competition from other drugs and the future launch of generics.”